問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Hematology & Oncology

Division of General Surgery

Chia-Yi Christian Hosptal

更新時間：2023-09-19

蘇進成
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

32Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇進成

List

45Cases

2013-12-01 - 2021-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2021-02-08 - 2023-07-20

Phase III

A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease

  • Condition/Disease

    ER (+), HER2 (-) breast cancer

  • Test Drug

    SAR439859

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2022-03-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2014-05-01 - 2029-12-31

Phase III

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

  • Condition/Disease

    primary breast cancer

  • Test Drug

    Olaparib

Participate Sites
12Sites

Terminated12Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

2019-01-01 - 2026-06-30

Phase III

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

  • Condition/Disease

    Hormone Receptor-positive, HER2-negative Early Breast Cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting9Sites

2016-06-01 - 2025-05-31

IIT

Phase III

Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative Locally Advanced Breast Cancer undergoing treatment with nabpaclitaxel and carboplatin

  • Condition/Disease

    Triple Negative Locally Advanced Breast Cancer

  • Test Drug

    atezolizumab (MPDL3280A)

Participate Sites
7Sites

Terminated5Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

侯明鋒
Kaohsiung Municipal Gangshan Hospital

未分科

2019-07-01 - 2021-12-23

Phase III

A Phase III Randomized, Double-Blind, Neoadjuvant Study of Hormonal Therapy Plus Palbociclib Versus Hormonal Therapy Plus Placebo in Women With Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

  • Condition/Disease

    Primary Breast Cancer

  • Test Drug

    Ibrance

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Condition/Disease

    HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Test Drug

    Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中
Taipei Veterans General Hospital

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2023-11-01 - 2026-12-31

Phase III

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

  • Condition/Disease

    Metastatic Breast Cancer

  • Test Drug

    Lasofoxifene

Participate Sites
7Sites

Recruiting7Sites

2018-08-31 - 2026-05-31

Phase III

A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ADJUVANT ANTHRACYCLINE/TAXANE-BASED CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE IN PATIENTS WITH OPERABLE TRIPLE-NEGATIVE BREAST CANCER

  • Condition/Disease

    Triple-Negative Breast Cancer

  • Test Drug

    Atezolizumab (RO5541267)

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting1Sites

Terminated9Sites

曾令民
Taipei Veterans General Hospital

Division of General Surgery

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB